Real-world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia
- PMID: 38063326
- DOI: 10.1002/ajh.27129
Real-world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia
Comment on
-
Avatrombopag for adults with early versus chronic immune thrombocytopenia.Am J Hematol. 2024 Feb;99(2):155-162. doi: 10.1002/ajh.27080. Epub 2023 Dec 8. Am J Hematol. 2024. PMID: 38063420 Free PMC article.
References
REFERENCES
-
- Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104:1112-1123.
-
- Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393-402.
-
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-2393.
-
- Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172:262-273.
-
- Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019;185:503-513.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources